LAUSR

ABSTRACT In a previous study, we constructed a MHSP65‐TCL anti‐lung cancer vaccine with Lewis lung carcinoma TCL plus MHSP65, and illustrated its anti‐lung cancer effect through specific and nonspecific anti‐tumor immunity. However, TCL contains some immunoinhibit components such as FasL. If this component can be eliminated from TCL, the anti‐tumor immunity of MHSP65‐TCL constructed with TCL should be improved. In the present study, we knocked down FasL from Lewis lung carcinoma cells and prepared MHSP65‐(FasL‐/TCL) with this cell line's TCL. After further investigation, MHSP65‐(FasL‐/TCL) exhibited a better ability to reduce splenocytes apoptosis, promote its activation and secretion of secretingTNF‐&bgr;, IL‐2 compared with MHSP65‐(FasL +/TCL). Accordingly, specific and nonspecific antitumor immunity induced by MHSP65‐(FasL‐/TCL) is stronger than that of MHSP65‐(FasL +/TCL). In vivo, MHSP65‐(FasL‐/TCL) immunization can prolong survival of Lewis lung carcinoma bearing mice. Thus, we report that the anti‐lung cancer effect of MHSP65‐TCL can be improved by removal of FasL from the TCL. It provides a new route to construct MHSP65‐TCL and other antitumor vaccines based on TCL. HighlightsConstructed a MHSP65‐(FasL‐/TCL) anti‐lung cancer vaccine with the TCL removed FasL (FasL‐/TCL).MHSP65‐(FasL‐/TCL) can induce stronger nonspecific and specific anti‐lung cancer immunity than MHSP65‐(FasL+/TCL).MHSP65‐(FasL‐/TCL) immunization can prolong survival of tumor bearing mice compared with that of MHSP65‐(FasL+/TCL).Theoretically, the method eliminated FasL from TCL can be applied in all the immunotherapy based on TCL.